Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind study of HH2853 versus chidamide in relapsed/refractory peripheral T-cell lymphoma
CTR20261451Phase 3Active
- Sponsor
- Haihe
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HH2853, tucidinostat in peripheral T-cell lymphoma (PTCL), sponsored by Haihe. Started Jun 2026; status: active.
02
Drugs
HH2853tucidinostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on CTR20261451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261451.